Sutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Wall Street Zen

Sutro Biopharma (NASDAQ:STRO) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

STRO has been the topic of a number of other research reports. HC Wainwright restated a “neutral” rating and issued a $2.00 price target on shares of Sutro Biopharma in a research note on Tuesday, April 29th. Piper Sandler upgraded Sutro Biopharma from a “neutral” rating to an “overweight” rating and set a $2.00 price target on the stock in a research note on Monday, June 16th. Finally, Bank of America dropped their price target on Sutro Biopharma from $1.00 to $0.80 and set an “underperform” rating on the stock in a research note on Monday, May 19th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $6.11.

Sutro Biopharma Stock Up 0.3%

Shares of Sutro Biopharma stock opened at $0.80 on Friday. Sutro Biopharma has a 12-month low of $0.52 and a 12-month high of $5.17. The stock has a market cap of $68.02 million, a P/E ratio of -0.32 and a beta of 1.66. The business’s 50 day moving average is $0.81 and its 200-day moving average is $1.03.

Sutro Biopharma (NASDAQ:STRO) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.25. Sutro Biopharma had a negative return on equity of 481.57% and a negative net margin of 201.32%. The company had revenue of $63.74 million for the quarter, compared to analysts’ expectations of $14.55 million. On average, sell-side analysts expect that Sutro Biopharma will post -2.92 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Cerity Partners LLC bought a new position in Sutro Biopharma during the 1st quarter worth $25,000. Dynamic Technology Lab Private Ltd bought a new position in Sutro Biopharma during the 4th quarter worth $26,000. Vontobel Holding Ltd. increased its position in Sutro Biopharma by 100.0% during the 1st quarter. Vontobel Holding Ltd. now owns 50,000 shares of the company’s stock worth $33,000 after buying an additional 25,000 shares during the period. Savant Capital LLC bought a new position in Sutro Biopharma during the 2nd quarter worth $37,000. Finally, CWM LLC grew its holdings in shares of Sutro Biopharma by 73.2% during the 2nd quarter. CWM LLC now owns 56,657 shares of the company’s stock worth $40,000 after purchasing an additional 23,941 shares in the last quarter. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.